Company has been created for scientific elaboration and practical application of new biotechnological methods in human disease treatment, originated on applying fetal stem cells and tissues extract. Company in its development reviews elaborating new biotechnological rejuvenating creams on the origin of placental extract, likewise embedding in clinic the anti-aging biotechnological complex.

1. Fetal Stem Cells in Chronic Wounds
& Ulcer Treatment
DOCTOR
ANDRII KUKHARCHUK
13 Apr, 2015

2. CHRONIC WOUND AND ULCER
The mainstay of therapy for
severe, limb-threatening ischemia is
either surgical or endovascular
revascularization aiming to improve
blood flow to the affected
extremity. If revascularization has
failed or is not possible, major
amputation is often necessary. This
relates to about 30% of all cases of
severe limb ischemia,
corresponding to about 100.000
major leg amputations in the EU,
and to 120.000 in the US.
Leg amputation in atherosclerotic
PAD causes an acute mortality rate
of around 30% and a grim five-year
prognosis with a survival rate of less
than 30%.

3. CHRONIC WOUND AND ULCER
Nonhealing chronic wounds are a
large and growing problem with an
incidence of 5–7 million cases per
year in the United States only.
Chronic wounds are a cause of
significant morbidity and mortality
and pose a large financial burden on
the healthcare system.
Despite the most recent advances
in wound management, up to 50%
of chronic wounds still fail to heal.
Regenerative potential of fetal
progenitor cells can help in
treatment of no healing wounds by
3 target points: activation of
angiogenesis, induction of immune
tolerance, and repair and
regeneration of the skin.

4. CHRONIC WOUND AND ULCER
Patient R., 66 yrs, M., Diabetic
Ulcer.
Ulcer not healing during 120 days
Doppler Study before treatment:
Minimal flow is seen in the
posterior tibial artery in the upper
leg and the superior margin of the
wound.
There is almost complete block of
the posterior tibial artery at the
junction of the upper and mid third
of the leg.
Flow is mildly reduced in anterior
tibial artery and dorsalis paedis
artery around the ankle and in the
foot.
Screening Photo
Before commencement of
treatment

5. CHRONIC WOUND AND ULCER
Patient R., 66 yrs, M., Diabetic Ulcer.
1st Step of Fetal Stem Cells
Treatment:
Intravenous infusion of fetal liver
hematopoietic stem cells (AC133+)
& subcutaneously injection of neural
stem cells from same fetus.
Aim:
Hematopoietic stem cells introduce
immunologic tolerance for all kinds
of allogenic stem cells from same
fetus + improve endothelial
regeneration in arteries and veins.
 Neural fetal stem cells restore
innervations in zone of diabetic
neuropathy.

6. Patient R., 66 yrs, M., Diabetic
Ulcer.
2nd Step of Fetal Stem Cells
Treatment:
Local multiple injection of fetal
angioblasts and fetal
neuroblasts along obliterated
arteries
Aim
Creation new vascular
network by stimulation of
angiogenesis and
vasculogenesis.
Restore local innervations in
ischemic legs' tissue.

7. Patient R., 66 yrs, M., Diabetic
Ulcer.
3rd Step of Fetal Stem Cells
Treatment:
Local multiple injection of fetal
angioblasts and fetal neuroblasts
around the ulcer and in the
bottom of the wound.
Aim
Creation new local vascular
network by stimulation of
angiogenesis and vasculogenesis.
Restore local innervations in
ischemic tissue of wound.

8. Patient R., 66 yrs, M., Diabetic Ulcer.
4rd Step of Fetal Stem Cells
Treatment:
Application of fetal tissue extracts
(skin, muscle and umbilical cord) in
autoplasma gel.
Aim
Activation of wound epithelialization

9. Patient R., 66 yrs, M., Diabetic Ulcer.
14 days after introduction of cells. Wound on 14th day covered
ointment with recombinant epidermal growth factor.
No epithelialization

10. Patient R., 66 yrs, M., Diabetic Ulcer.
17 days after introduction of cells. Wound covered with
colloid silver and fetal skin extract gel.
No epithelialization.

11. Patient R., 66 yrs, M., Diabetic Ulcer.
20 days after introduction of cells. Size of the wound
reduced. Wound cleaned from dead tissue and covered
with colloid silver and fetal skin extract gel.
No epithelialization

12. Patient R., 66 yrs, M., Diabetic Ulcer.
24 days after introduction of cells. Wound cleaned from
dead tissue. Implantation of 4 flaps (black arrow) fetal
skin (14-15 weeks of gestation). Free surface
uncovered area by fetal skin of the wound covered
with colloid silver and placental extract

13. Patient R., 66 yrs, M., Diabetic Ulcer.
30 days after introduction of cells. 5 days after implantation
of fetal skin. Flaps of fetal skin absorbed. Epithelialization
of edges started from all sides of wound (black arrow)
under the impact of growth factors secreted from fetal
skin

14. Patient R., 66 yrs, M., Diabetic Ulcer.
31 days after introduction of cells. Repeated implantation of
fetal skin for strengthening and acceleration of wound
epithelialization.

15. Patient R., 66 yrs, M., Diabetic
Ulcer.
46 days after introduction of cells.
Repeated implantation of fetal skin
(black arrow) + ointment "EPC-
Universal":
► Amorphous Hydrogel Wound
Dressing with Colloidal silver
► Neomycin-Bacitracin
Sulphacetamide
► Fetal Hematopoietic Stem Cells
Extract
► Fetal Neural Stem Cells Extract
► Fetal Thymus Extract
► Fetal Umbilical Cord Tissue
Extract
► Fetal Spleen Extract
► Fetal Muscle & Skin Extracts

16. Patient R., 66 yrs, M., Diabetic
Ulcer.
48 days after introduction of cells.
Wound epithelialization is weak.
Offered to make patient
autologous skin transplantation
with implantation of fetal skin.
But patient refused the operation.
Autoskin
graftFetal skin
implants

17. Patient R., 66 yrs, M., Diabetic Ulcer.
49 days after introduction of cells. Wound
epithelialization is weak.
Second local multiple injections of fetal
angioblasts and fetal neuroblasts around
the wound.
Repeated implantation of fetal skin.
HbA1C:
Before treatment – 6.9%
Now – [? I HAVE NOT ANALYSES COPY!!!]
Estimated Average Glucose:
Before treatment – 151.9 mg/dl
Now – [? I HAVE NOT ANALYSES COPY!!!]
Doppler Study: Compared to previous
scan, there is extensive
neovascularisation is noted in the bed of
the wound.
Treatment continue

18. Patient R., 66 yrs, M., Diabetic Ulcer.
Before Fetal Stem Cells
Treatment
Now
(in Process of Fetal Stem Cells
Treatment)

19. Patient K., Male, Diabetic Foot.
Necrotized tissues are observed
(black arrow), canal filled with
pus (white arrow)
Wound not healing during 90
days
Doppler Study before treatment:
Generalised atherosclerotic
disease involving arteries of
right lower limb.
Extensive wall calcification is
seen in anterior tibial artery,
posterior tibial artery and
dorsalis paedis artery.
Screening Photo
Before commencement of
treatment

20. Patient K., Male, Diabetic
Foot.
Necrotized tissues are removed.
Two pus canals are cleaned
(white arrow)

21. Patient K., Male, Diabetic Foot.
Schematic representation of local wound treatment: points for
cells introduction

22. Patient K., Male, Diabetic
Foot.
Treatment:
1st Step. Intravenous infusion of
fetal liver hematopoietic stem
cells (AC133+) & subcutaneously
injection of neural stem cells
from same fetus.
2nd Step. Local multiple injection
of fetal angioblasts and fetal
neuroblasts along obliterated
arteries.
3rd Step. Local multiple injection
of fetal angioblasts and fetal
neuroblasts around the ulcer and
in the bottom of the wound
(foto).
4rd Step. Application of fetal
tissue extracts (skin, muscle and
umbilical cord) in autoplasma gel.

23. Patient K., Male, Diabetic Foot.
6 days after introduction of cells. Edges of wound constringes.
Epithelializiation of wound started in the wound edges (white arrow)
Granulation is clean covered with fibrin in some places (black arrow).
Patient walks independently. Not febrile.

24. Patient K., Male, Diabetic Foot.
10 days after introduction of cells. Clean wound canal closed
(black arrow). New skin epithelium “creeps” on the granulation
(white arrow). Patient walks independently. Not febrile.

25. Patient K., Male, Diabetic Foot.
14 days after introduction of cells. Wound clean and canal is probed
(black arrow), no pus. Epithelialization continues. Wound closed with
ointment with recombinant epidermal growth factors. Patient walks
independently. Not febrile.

26. Patient K., Male, Diabetic Foot.
17 days after introduction of cells. Clean
wound and canal probed; no pus. In the
canal and on the wound – ointment with
colloid silver and fetal skin extract.
Epithelialization continues. Patient
walks independently. Not febrile.

27. Patient K., Male, Diabetic Foot.
20 days after introduction of cells. Purulence of canal, febrile,
severe pain. Clean wound, canal probed, pus removed.

28. Patient K., Male, Diabetic Foot.
20 days after introduction of cells. In the canal and on wound –
ointment with colloid silver and fetal skin extract.

29. Patient K., Male, Diabetic Foot.
20 days after introduction of cells. Continuous epithelialization of
wound edges. Intramuscular cephalosporin 5th generation
prescribed.

30. Patient K., Male, Diabetic Foot.
24 days after introduction of cells. Again pus in the canals.
Wound is cleaned, canals probed and washed, pus removed. In
canals – antibiotic ointment. On the wound – colloid silver gel
and placental extracts. Continuous epithelialization of wound
edges.

31. Patient K., Male, Diabetic Foot.
30 days after introduction of cells. Canals probed and washed. No
pus. Continuous epithelialization of wound edges.

32. Patient K., Male, Diabetic Foot.
30 days after introduction of cells. In canals antibiotic ointment
were introduced. Wound covered with colloid silver gel and
placental extracts. Comparison foto: 3 days vs 30 days
3 days 30 days

33. Patient K., Male, Diabetic Foot.
31st day: implantation of fetal skin for strengthening and
accelerating epithelialization of wound under the impact of fetal
growth factors.

34. Patient K., Male, Diabetic Foot.
37st day: accelerating of wound epithelialization. Wound covered
with colloid silver gel and placental extracts.

35. Patient K., Male, Diabetic Foot.
38th day: pus in wound canals. Canal open and clearing.

36. Patient K., Male, Diabetic Foot.
From 38th to 44th days: Wound covered with ointment “EPC
Universal”.

37. Patient K., Male, Diabetic Foot.
46th days: Wound covered with ointment “EPC Universal”. In
canal – ointment “Levomicol”

38. Patient K., Male, Diabetic
Foot.
49th days: implantation of fetal
skin for strengthening and
accelerating epithelialization of
wound under the impact of fetal
growth factors.
HbA1C:
Before treatment – 9.2%
Now – [? I HAVE NOT THIS
ANALYSES!!!]
Doppler Study: Compared to previous
scan, there is extensive
neovascularisation is noted in the bed
of the wound.
Treatment continue

39. Patient K., Male, Diabetic Foot.
Before Fetal Stem Cells
Treatment
Now

40. Patient Ch., M., Thromboangiitis
obliterans (Berger's disease)
Wound not healing during 120 days
Doppler Study before treatment:
[??? - I HAVE NOT THIS DATA!!!
IMAGINE ONLY!!!]
Screening Photo
Before commencement of
cells' treatment

41. Patient Ch., M., Thromboangiitis
obliterans (Berger's disease)
Treatment:
1st Step. Intravenous infusion of
fetal liver hematopoietic stem
cells (AC133+) &
subcutaneously injection of
neural stem cells from same
fetus.
2nd Local multiple injection of
fetal angioblasts and fetal
neuroblasts around the ulcer
and in the bottom of the wound
(foto).
3rd Step. Application of fetal
tissue extracts (skin, muscle
and umbilical cord) in
autoplasma gel.
Local introduction of cells

42. Patient Ch., M., Thromboangiitis obliterans (Berger's
disease)
14 days after introduction of cells. Infection, pus.
Prescribed I/M Gentamycin, 80 mg 2 times per day.
Wound is covered with disinfecting cream “Hydroheal AM” with
the colloid silver

43. Patient Ch., M., Thromboangiitis obliterans (Berger's
disease)
17 days after introduction of cells. Infection, pus. Wound cleaned
from pus.
Prescribed I/M Gentamycin, 80 mg 2 times per day.
Wound is covered with disinfecting cream “Hydroheal AM” with
the colloid silver + fetal skin extract

44. Patient Ch., M., Thromboangiitis obliterans (Berger's
disease)
20 days after introduction of cells. Infection, pus.

45. Patient Ch., M., Thromboangiitis obliterans (Berger's disease)
20 days after introduction of cells. Wound cleaned.

46. Patient Ch., M., Thromboangiitis obliterans (Berger's disease)
20 days after introduction of cells. Applied antibiotic ointment on
wound: Mupirocin Oiment IP. Intramuscular cephalosporin 5th
generation.

47. Patient Ch., M., Thromboangiitis obliterans (Berger's
disease)
24 days after introduction of cells. Purulence and edema on the
2nd toe. Wound cleaned. Applied antibiotic ointment on wound:
Mupirocin Oiment IP. Intramuscular cephalosporin 5th
generation. After demarcation line appears planned for
amputation of 2nd toe.

48. Patient Ch., M., Thromboangiitis obliterans (Berger's
disease)
30 days after cells introduction. Toe amputation. Wound cleaned
from pus.

49. Patient Ch., M., Thromboangiitis
obliterans (Berger's disease)
30 after cells introduction. Antibiotic
ointment applied on wounds.
On 31st day planned to apply antibiotic
ointment + fetal extract of liver with
high content of tissue fibrinolysis
activator.
In cases of TAO in the zone of
debridement micro-thrombosis are
formed which blocks blood supply to
small portions of the wound surface. As
a result these portions in the wound
constantly necrotize and form
purulence. Activation of local
fibrinolysis in wounds under impact of
fetal liver extract can restore blood
supply to small vessels and prevent
small necrosis in the wounds.

50. Patient Ch., M., Thromboangiitis
obliterans (Berger's disease)
On 31st day was apply antibiotic ointment +
fetal extract of liver with high content of
tissue fibrinolysis activator.

51. Patient Ch., M., Thromboangiitis
obliterans (Berger's disease)
38 days: pus. On the wound - antibiotic
ointment Bactroban. Per os – Warfarin
& Trental

52. Patient Ch., M., Thromboangiitis
obliterans (Berger's disease)
40 days: wound clearing.
Granulation appear. On the wound
- antibiotic ointment Bactroban.

53. Patient Ch., M., Thromboangiitis
obliterans (Berger's disease)
41 days: wound epithelialization
starting. On the wound - ointment
"EPC Universal".

54. Patient Ch., M., Thromboangiitis
obliterans (Berger's disease)
46 days: fetal skin implantation.

55. Patient Ch., M., Thromboangiitis obliterans (Berger's disease)
48 days: wound epithelialization continue.

56. Patient Ch., M., Thromboangiitis obliterans (Berger's disease)
48 days: wound epithelialization continue. On the wound – ointment
"EPC Universal"

57. Patient Ch., M.,
Thromboangiitis obliterans
(Berger's disease)
49 days: fetal skin implantation.
Doppler Study:
Compared to previous study,
there is marginal improvement in
the vascularity of the wound.
Treatment continue

58. Patient Ch., M., Thromboangiitis obliterans (Berger's disease)
Before Fetal Stem Cells
Treatment
Now
(after 3.5 months)
48 days after Fetal Stem Cells
Treatment

59. THANK YOU